News

Yesterday, the FDA took a major step toward officially approving Paxlovid. Catch up on this story and the other top COVID-19 news updates from the past week.

Former NBA star Magic Johnson has partnered with GSK to educate the public about this virus, specifically in seniors and those at high-risk for contracting a severe form of RSV.

For preterm infants, clinical outcomes from microbial mechanisms are not affected by a diet of only human milk compared to bovine milk formulas or fortifiers.

The investigators found the risk of hospital-acquired Clostridioides difficile (CDI) infection increased when a hospital switched to serving only coronavirus disease 2019 patients.

The FDA's Antimicrobial Drugs Advisory Committee recommended approving Pfizer’s New Drug Application for Paxlovid to treat mild-to-moderate COVID-19 in adults at high risk of severe or fatal disease progression.

The federal agency has taken a vital role in support and implementation of the ongoing PEPFAR initiative.

These investigators concluded Omicron XBB.1.5 the most successful COVID-19 variant of its lineage.

Bemnifosbuvir, the investigational therapy, demonstrated favorable data that was announced at this week's 2023 International Conference on Antiviral Research.

With this FDA emergency use authorization (EUA), all persons 6 months and older are now eligible to receive the Pfizer-BioNTech Omicron BA.4/BA.5-adapted bivalent booster.

This study analyzed concerns that a lack of time may lead primary care physicians to prescribe unnecessarily as a “quick fix.”

An investigator who helped draft the new recommendations discusses universal screening, the challenges of risk-based testing, and the overall goals of reducing HBV incidence rates.

The risk of congenital heart diseases in offspring was increased among mothers with preconception previous hepatitis B virus (HBV) infection.

Cirrhosis, older age, and vaccine type were among factors associated with lower antibody responses to COVID-19 vaccines in patients with chronic liver disease, new research shows.

In the White House’s new budget they have put aside several billion dollars towards establishing a hepatitis C (HCV) program. In addition, an HCV vaccine is expected to go into phase 1 clinical trials this year, and a pharmaceutical company is working with states to gain better therapeutic access.

COVID-19 patients had a significantly higher risk of cardiovascular disease and death in both the short- and long-term.

“Real-world” assessment finds nirmatrelvir-ritonavir reduces risk of severe COVID-19 from BA4 and BA5 omicron subvariants.

The benefits of COVID-19 vaccines waned over time and were less effective against the Omicron variant of the virus, a long-term meta analysis found.

A 4-dose COVID-19 vaccine regimen and prior infection with either the BA.1 or BA.2 variants were extremely effective against the Omicron BA.5 subvariant.

Global health officials highlighted an urgent need to ramp up efforts to eliminate viral hepatitis, with 1 million deaths annually at stake.

58.5% of an infant’s microbiota composition is transferred by their mother.

Investigators see a potential new approach to therapeutic development for C diff.

One of the most significant recommendations is for all adults to be tested for the virus at least once in their lifetime.

Nasal administration of the fully human anti-CD3 monoclonal antibody Foralumab modulated T cell inflammatory responses in COVID-19.

The companies, Apotex and Pharmedica, are doing this action due to concerns of sterility of the products.

A healthcare worker and a patient with HIV concomitantly provide important clinical considerations.

The congressional bill has been on Capitol Hill for over 2 years now, and the interested stakeholders are continuing their lobbying efforts to get it passed.

Enteric pathogens increase C difficile virulence by providing amino acids that shape the metabolic environment in the gut.